Emotive builds an application-form digital therapeutic that uses cognitive modeling and machine learning to deliver games and coaching to improve cognitive skills and behavior for ADHD patients. The product has won a CES 2023 Innovation Award and a Red Dot Design Award, signaling external recognition for its innovation and design. The company received approval from the Ministry of Food and Drug Safety to run a confirmatory clinical trial for ADHD digital therapeutics. Emotive plans to begin that confirmatory trial in January 2024 at Seoul National University Hospital and Hanyang University Hospital. The firm aims to validate safety and efficacy to pursue medical device approval domestically and a U.S. FDA 510(k) clearance. Emotive says it will use the new funding to accelerate R&D, domestic and international clinical and regulatory preparation, and overseas business expansion.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2024